We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Diagnostic Test Evaluated for Gram-Positive Bloodstream Infections

By LabMedica International staff writers
Posted on 13 Jan 2015
Print article
The Verigene Gram-positive blood culture assay systems
The Verigene Gram-positive blood culture assay systems (Photo courtesy of NANOSPHERE)
A microarray-based rapid diagnostic test, which includes targets for 12 bacterial species and three resistance determinants, has been compared to routine microbiologic methods for diagnostic accuracy.

Overall mortality in patients with Gram-positive bacteremia ranges from 10% to 40%, with delays in effective antimicrobial therapy leading to a dramatic increase in mortality and patients with Gram-positive bacteremia also often suffer from substantial long-term morbidity as a result of prolonged hospitalization and generalized deconditioning.

Scientists at the University of Houston (TX, USA) and their colleagues examined blood cultures submitted as part of routine clinical care to a 650-bed tertiary care hospital. All blood cultures with Gram stain identification of Gram-positive cocci between October and December 2013 were prospectively screened for eligibility. Blood cultures were obtained using BacT/ALERT (bioMérieux; Durham, NC, USA) aerobic (FA) and anaerobic (SN) blood culture bottles and incubated in the bioMérieux BacT/ALERT 3D automatic monitoring system.

The Verigene Gram-positive blood culture assay (BC-GP, Nanosphere, Inc.; Northbrook, IL, USA) is a microarray-based rapid diagnostic test that identifies molecular target through DNA extraction and subsequent hybridization to complementary oligonucleotides present on the microarray grid. A secondary oligonucleotide affixed to a gold nanoparticle is then hybridized to captured bacterial DNA, and the target is identified through analysis of the relative optical density of the probes on the panel. Total hands-on time was approximately 10 minutes with a 2.5-hour test run time.

A total of 143 consecutive patients with Gram-positive bacteremia were included in the analysis. BC-GP correctly identified 127/128 (99.2%) of organisms from monomicrobial blood cultures and 9/14 (64.3%) from polymicrobial, including all methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. Stewardship interventions were possible in 51.0% of patients, most commonly stopping or preventing unnecessary vancomycin or starting a targeted therapy.

The authors concluded that the BC-GP is a potentially useful tool for antimicrobial stewardship programs to improve the care of patients with Gram-positive bacteremia. In Monte Carlo simulations, unnecessary antibiotics could be stopped at least 24 hours earlier in 65.6% of cases, and targeted therapy could be started at least 24 hours earlier for 81.2% of the patients. The study was published in the January 2015 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

University of Houston
bioMérieux 
Nanosphere, Inc. 


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Immunoassays and Calibrators
QMS Tacrolimus Immunoassays
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.